Sign In
Buy DSNKY
$16.12
-1.81 (-10.09%)
At Close: Jul 31, 2026
Daiichi Sankyo Company, Limited (DSKYF) Q4 2023 Earnings Call Transcript
11:50pm, Thursday, 25'th Apr 2024
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q4 2023 Earnings Call Transcript April 25, 2024 2:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Department Hiroyuki Okuza
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
05:36pm, Friday, 05'th Apr 2024
The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor.
Daiichi Sankyo Company, Limited (DSKYF) Q3 2023 Earnings Call Transcript
09:45pm, Thursday, 01'st Feb 2024
Daiichi Sankyo Company, Limited (DSKYF) Q3 2023 Earnings Call Transcript
Esperion resolves legal dispute with Daiichi Sankyo ahead of likely European drug approval
12:15pm, Wednesday, 03'rd Jan 2024
Esperion Therapeutics has reached a deal with Daiichi Sankyo to resolve a commercial dispute with an amendment to their ongoing collaboration. Daiichi Sankyo Europe GmbH, the company's European arm
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
07:00am, Wednesday, 03'rd Jan 2024
Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE) the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (TSE: 4568), annou
Depixus Announces Strategic Collaboration With Daiichi Sankyo to Use MAGNA™ Technology to Accelerate RNA-targeted Drug Discovery
03:18am, Tuesday, 12'th Dec 2023
PARIS--(BUSINESS WIRE)--Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA™ technology to accelerate the Japanese healthcare leader's RNA-targeted
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH.
Japan panel recommends approval of updated Daiichi Sankyo COVID shot- Kyodo
07:47am, Monday, 27'th Nov 2023
A Japanese health ministry panel on Monday recommended approval for an updated version of Daiichi Sankyo's COVID-19 vaccine, the Kyodo news agency said.
Japan to buy 1.4 mln doses of Daiichi Sankyo COVID vaccine
09:04pm, Thursday, 16'th Nov 2023
Japan's health ministry said on Friday it agreed to buy 1.4 million doses of Daiichi Sankyo's updated COVID-19 vaccine.
Change in Leadership at Daiichi Sankyo Europe
02:00am, Monday, 06'th Nov 2023
MUNICH--(BUSINESS WIRE)--Today, Daiichi Sankyo Europe GmbH, the European headquarter organisation of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd., announced the appointment of its new
Daiichi Sankyo: Merck Partnership Poises Both Companies For ADC Expansion
09:02am, Monday, 23'rd Oct 2023
Daiichi Sankyo has entered into a collaboration with Merck for three antibody-drug conjugates, bringing in a significant upfront payment and potential milestone payments. The three drugs in developmen
Trending Tickers: AT&T, Merck-Daiichi Sankyo, Klaviyo: Trending tickers October 29, 2023
05:44pm, Friday, 20'th Oct 2023
Scotiabank analysts upgrade AT&T (T) stock from "Sector Perform" to "Sector Outperform." Merck (MRK) strikes a deal worth up to $22 billion with Japanese pharmaceutical company Daiichi Sankyo (4568.T)
Merck and Daiichi Sankyo Strike Cancer Drug Deal Worth Up to $22 Billion
10:30am, Friday, 20'th Oct 2023
Drugmaker Merck (MRK) agreed to pay Daiichi Sankyo $5.5 billion for the rights to jointly develop and commercialize three of the Japanese company's candidate cancer drugs.
Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck
10:40pm, Thursday, 19'th Oct 2023
Daiichi Sankyo shares 4568, +12.21% rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck MRK, -1.53% to jointly develop and commercialize three cancer drug candida
Daiichi Sankyo and Merck team up on $22 bln collaboration for Sankyo's antibody drug conjugates
07:46pm, Thursday, 19'th Oct 2023
Daiichi Sankyo and Merck have entered into an agreement worth up to $22 billion for three of Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates, the companies said on Thursday.
